Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Interaction Study of GSK3640254 and Dolutegravir in Healthy Subjects
NCT03816696Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fipravirimat in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir at Day 7, Maximum Observed Concentration (Cmax) of Dolutegravir at Day 7 and 4 more. Started Jan 2019; status: completed.
02
Drugs
fipravirimat
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03816696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816696.